Piramal Pharma Share Price: Piramal Pharma is a well-known pharmaceutical company excelling in the manufacture and delivery of pharmaceutical products. It’s steadily climbing the economic ladder, becoming a key player thanks to its significant contributions to the production of complex consumer healthcare items.
Below is a detailed assessment of Piramal Pharma’s current share price graph, market analysis, overall market situation, share price targets from 2024 to 2030, financial projections, annual income statement, and additional relevant information.
Piramal Pharma Solutions Company Overview
| Company Name | Piramal Pharma Solutions Ltd. |
| Founded | 2020 |
| Headquarters | Mumbai, Maharashtra |
| Industry | Pharmaceutical |
| Chairman | Nandini Piramal |
| Stock Exchange Listing | NSE & BSE |
| Official Website | piramalpharma.com |
Piramal Pharma Solutions Fundamental Analysis
| Metric | Value |
|---|---|
| Market Cap | ₹35,165.47 Cr. |
| ROE | 6.55% |
| ROCE | 8.33% |
| P/E | 54.71 |
| P/B | 5.01 |
| Div. Yield | 0.04% |
| Book Value | ₹52.95 |
| Face Value | ₹10 |
| EPS (TTM) | ₹4.85 |
| 52 Week High | ₹307.90 |
| 52 Week Low | ₹114.35 |
Also Read: Sky Gold Share Price Target
Piramal Pharma Solutions Financials
Income Statement
| (INR) | 2024 | Y/Y change |
|---|---|---|
| Revenue | 81.71B | 15.39% |
| Operating expense | 44.49B | 7.09% |
| Net income | 178.20M | 109.56% |
| Net profit margin | 0.22 | 108.37% |
| Earnings per share | 0.19 | 112.57% |
| EBITDA | 11.39B | 97.62% |
| Effective tax rate | 90.06% | — |
Balance Sheet
| (INR) | 2024 | Y/Y change |
|---|---|---|
| Cash and short-term investments | 5.02B | -19.47% |
| Total assets | 153.12B | 5.43% |
| Total liabilities | 74.00B | -4.50% |
| Total equity | 79.11B | — |
| Shares outstanding | 1.32B | — |
| Price to book | 4.20 | — |
| Return on assets | 1.93% | — |
| Return on Capital | 2.30% | — |
Cash Flow
| (INR) | 2024 | Y/Y change |
|---|---|---|
| Net income | 178.20M | 109.56% |
| Cash from operations | 10.05B | 107.60% |
| Cash from investing | -4.34B | 67.58% |
| Cash from financing | -4.22B | -151.65% |
| Net change in cash | 1.66B | 619.44% |
| Free cash flow | -1.17B | 86.66% |
Also Read: Cochin Shipyard Share Price Target
Piramal Pharma Share Price Target From 2024 to 2030
| Year | Target Price |
|---|---|
| Piramal Pharma Share Price Target 2024 | ₹290 |
| Piramal Pharma Share Price Target​ 2025 | ₹415 |
| Piramal Pharma Share Price Target 2026 | ₹522 |
| Piramal Pharma Share Price Target 2027 | ₹680 |
| Piramal Pharma Share Price Target 2028 | ₹821 |
| Piramal Pharma Share Price Target 2029 | ₹967 |
| Piramal Pharma Share Price Target 2030 | ₹1135 |
Piramal Pharma Solutions Shareholding Pattern
- Retail & Other: 31.73%
- Promoters: 34.95%
- Foreign Institutions: 31.73%
- Mutual Funds: 11.21%
- Other Domestic Institutions: 2.59%%
Also Read: Wockhardt Pharma Share Price Target
Piramal Pharma Competitors/Peer Companies
- Suven Pharma
- Laurus Labs
- JBCPL
- Emcure Pharma
- Natco Pharma
- Wockhardt
- Concord Biotech
- Granules India
- Glenmark Life
- Akums Drugs & Pharmaceuticals
Also Read: PC Jeweller Share Price Target
To connect with us, click on any of the given social media buttons.
FAQs
What is the Piramal Pharma Solutions Share Price Prediction 2025?
By 2025, Piramal Pharma’s share price is projected to rise to 415 INR. This significant increase reflects the company’s efforts to expand its product portfolio, enhance operational performance, and tap into new markets. The growth of its complex hospital generics business, along with rising demand for its consumer healthcare products, is likely to drive revenue growth. Additionally, strategic acquisitions and partnerships will further strengthen its market position, contributing to the expected rise in share price.
What is the Piramal Pharma Solutions Share Price Prediction 2026?
In 2026, the share price is anticipated to reach 522 INR. The company is expected to benefit from the full-scale realization of its ongoing investments in R&D, leading to the development of innovative products and solutions. Furthermore, the expansion of its global footprint, particularly in high-growth markets, is expected to drive higher revenues and profitability. The company’s commitment to enhancing its operational capabilities will also play a crucial role in achieving this target.
What is the Piramal Pharma Solutions Share Price Prediction 2027?
By 2027, the share price is projected to reach 680 INR. This growth is expected to be fueled by a combination of sustained revenue growth, improved profit margins, and successful execution of its growth strategies. The company’s focus on innovation and its ability to deliver high-quality, cost-effective pharmaceutical products will enhance its competitive position in the market. Additionally, increased adoption of its complex hospital generics and consumer healthcare products in international markets will contribute to this substantial rise in share price.
What is the Piramal Pharma Solutions Share Price Prediction 2029?
By 2029, the share price is expected to be 967 INR. This projection is based on the assumption that the company will successfully capitalize on growing opportunities in the pharmaceutical sector, including increasing demand for complex hospital generics and innovative consumer healthcare products. The company’s ability to adapt to changing market dynamics, coupled with its strong financial position, will likely support sustained growth. Additionally, the potential for strategic mergers and acquisitions could provide further impetus for share price appreciation.
What is the Piramal Pharma Solutions Share Price Prediction 2030?
In 2030, the share price of Piramal Pharma is anticipated to reach 1135 INR. This target reflects the company’s potential to become a major player in the global pharmaceutical industry. Continued investment in R&D, strategic expansion into new markets, and a focus on innovation are expected to drive significant revenue growth and profitability. Furthermore, the company’s strong management, robust business model, and ability to navigate regulatory challenges will position it for long-term success, making it an attractive stock for both domestic and international investors.
Disclaimer: The information in this blog is for educational purposes only, and the targets mentioned in it are given as suggestions by market analysts. Therefore, before investing your money in any company, it is mandatory to get complete information about the company and consult your financial advisor.
